MedWatch

Small Danish biotech firm to advise US authorities: "It opens a lot of doors"

The young Danish biotech company Cobo Technologies will advise the FDA on clinical trials with the genome editing tool CRISPR. The company's proprietary product can potentially become the standard quality control of CRISPR-based treatments.

Foto: Cobo Technologies

A small Danish biotech company will soon influence future drug development with one of the world's most promising technologies.

One year old Cobo Technologies has been appointed to a consortium under the US National Institute of Standards and Technology (NIST) that is to advise the health authorities on clinical trials with the promising genome editing tool, CRISPR.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier